RudaCure, a domestic company specializing in 感觉障碍 treatment development, announced the completion of its 日本ese 专利注册 for 非麻醉性镇痛药 technology targeting TRPV1 (瞫时受体电位香草酸亚型1). This 日本ese 专利注册 is considered an important milestone in protecting the 知识产权 of RudaCure's core technology. Currently, the same foundational 专利 has been filed in major markets including 中国, 美国, and 欧洲, with 日本 being the first to complete registration.
The TRPV1 antagonist-based 镇痛 being developed by RudaCure is attracting attention as a next-generation 疼痛治疗药 solution that can address the 成瘾性 and 副作用 of existing 麻醉性镇痛药. TRPV1 is an 离子通道 that plays a crucial role in 疼痛信号传导, and by selectively inhibiting it, powerful 镇痛效果 can be achieved without 副作用. RudaCure, a domestic neurodegenerative disease 初创企业, is researching antagonist-based 镇痛 drugs that can directly inhibit TRPV1 activity, and is expanding its 药物开发 管线 through 联合研究 with 嘉泉大学医学院 and global CROs.
An industry insider explained that "The completion of 日本ese 专利注册 is significant in that it expands 知识产权 protection for RudaCure's core technology into the world's third-largest 制药 market," adding that "日本 is one of the world's largest markets for 疼痛治疗药s and 眼科 drugs, and this 专利注册 can serve as an important foundation for future licensing and partnership strategies."
RudaCure's TRPV1 modulation technology is applicable not only to 疼痛治疗药 but also to 眼科 disease treatment such as 干眼症, showing potential to generate value across multiple therapeutic areas. The company's lead 管线, 干眼症治疗药 RCI001, has recently obtained 美国 FDA Phase 2 IND approval, and plans to expand the scope of 专利 protection for its core compound, which also demonstrates 镇痛疗效. 日本 is a major market for 制药 development, and this 专利注册 is expected to serve as a strategic bridgehead for 日本ese domestic licensing and 联合开发 partnerships. RudaCure plans to proceed with 专利注册s in 中国, 美国, and 欧洲, and will continue to strengthen its 知识产权 portfolio.